<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456686</url>
  </required_header>
  <id_info>
    <org_study_id>17513</org_study_id>
    <secondary_id>H0P-MC-OA01</secondary_id>
    <nct_id>NCT04456686</nct_id>
  </id_info>
  <brief_title>Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis</brief_title>
  <official_title>Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to test the safety and efficacy of LY3016859 for the treatment of
      osteoarthritis pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP)
      which is a protocol to accelerate the development of new treatments for chronic pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">March 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline in Average Pain Intensity as Measured by the NRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Western Ontario and McMaster University Arthritis Index (WOMAC®) Pain Subscale</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the WOMAC® Pain Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the WOMAC® Stiffness Subscale</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the WOMAC® Stiffness Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the WOMAC® Physical Function Subscale</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the WOMAC® Physical Function Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for Overall Improvement as Measured by Patient's Global Impression of Change</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline for Overall Improvement as Measured by Patient's Global Impression of Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for Worst Pain Intensity as Measured by NRS</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline for Worst Pain Intensity as Measured by NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Visual Analog Scale (VAS) for Pain</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the VAS for Pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Sleep Scale from the Medical Outcomes Study (MOS Sleep Scale)</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the Sleep Scale from the MOS Sleep Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Medication</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Total Amount of Rescue Medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L)</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>LY3016859</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3016859 given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3016859</intervention_name>
    <description>LY3016859 given IV.</description>
    <arm_group_label>LY3016859</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given IV.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a visual analog scale (VAS) pain value ≥40 and &lt;95 during screening.

          -  Have a history of daily pain for at least 12 weeks based on participant report or
             medical history.

          -  Have a value of ≤30 on the pain catastrophizing scale.

          -  Have a body mass index &lt;40 kilograms per meter squared (kg/m²) (inclusive).

          -  Are willing to maintain a consistent regimen of any ongoing nonpharmacologic
             pain-relieving therapies (for example, physical therapy) and will not start any new
             nonpharmacologic pain-relieving therapies during study participation.

          -  Are willing to discontinue all pain medications for condition under study, except
             rescue medication permitted per protocol, for the duration of the study.

          -  Have presence of index knee pain for &gt;12 weeks at screening.

          -  Have an x-ray supporting diagnosis of osteoarthritis according to the American College
             of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of
             index knee.

          -  Are men, or women able to abide by reproductive and contraceptive requirements.

        Exclusion Criteria:

          -  Have second- or third-degree atrioventricular (AV) heart block or AV dissociation or
             history of ventricular tachycardia.

          -  Have had a procedure within the past 6 months intended to produce permanent sensory
             loss in the target area of interest (for example, ablation techniques).

          -  Have surgery planned during the study for any reason, related or not to the disease
             state under evaluation.

          -  Have, in the judgment of the investigator, an acute, serious, or unstable medical
             condition or a history or presence of any other medical illness that would preclude
             study participation.

          -  There is an inability to rule out other causative or confounding sources of pain in
             the primary condition under study.

          -  Have had cancer within 2 years of baseline, except for cutaneous basal cell or
             squamous cell carcinoma resolved by excision.

          -  Have a substance use disorder as defined by the Diagnostic and Statistical Manual of
             Mental Disorders (5th edition; DSM-5; American Psychiatric Association).

          -  Have congenital QT prolongation or QT interval corrected for heart rate using
             Fridericia's formula (QTcF) interval measurement &gt;450 milliseconds (msec) for male
             participants, &gt;470 msec for female participants, or &gt;480 msec for participants with
             bundle branch block.

          -  Have any clinically important abnormality at screening, as determined by investigator,
             in physical or neurological examination, vital signs, electrocardiogram (ECG), or
             clinical laboratory test results that could be detrimental to the participant or could
             compromise the study.

          -  Have a positive human immunodeficiency virus (HIV) test result at screening.

          -  Are, in the judgment of the investigator, actively suicidal and therefore deemed to be
             at significant risk for suicide.

          -  Have an intolerance to acetaminophen or paracetamol or any of its excipients.

          -  Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2
             years prior to screening.

          -  Are largely or wholly incapacitated and unable to participate fully in all protocol
             procedures, for example, bedridden or confined to a wheelchair, permitting little or
             no selfcare.

          -  Have presence of surgical hardware or other foreign body in the index knee.

          -  Have an unstable index joint (such as a torn anterior cruciate ligament).

          -  Have had a surgical procedure or therapeutic injection in the affected knee within 3
             months prior to starting the washout period.

          -  Have fibromyalgia, chronic pain syndrome, or other concurrent medical or arthritic
             conditions that could interfere with the evaluation of the index knee.

          -  Have a history of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis,
             ankylosing spondylitis, arthritis associated with inflammatory bowel disease,
             sarcoidosis, or amyloidosis.

          -  Have clinical signs and symptoms of active knee infection or crystal disease of the
             index knee.

          -  Have a history of infection in the index joint.

          -  Have a history of arthritis due to crystals (e.g., gout, pseudogout).

          -  Have ipsilateral hip osteoarthritis.

          -  Have had an intra-articular injection of hyaluronic acid within 24 weeks of screening.

          -  Have an estimated glomerular filtration rate (eGFR) of less than 70
             milliliters/minute/1.73m² during screening.

          -  Have any clinically serious or unstable cardiovascular, musculoskeletal disorder,
             gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic,
             pulmonary, dermatologic, immunologic, or ophthalmologic disease within 3 months of
             baseline.

          -  Have received any antibodies against nerve growth factor (NGF), or antibodies against
             EGFR, or EGFR tyrosine kinase inhibitors.

          -  Have a history of allergic reactions to monoclonal antibodies, or clinically
             significant multiple or severe drug allergies, including but not limited to erythema
             multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or
             exfoliative dermatitis.

          -  Have a history or presence of uncontrolled asthma, eczema, significant atopy,
             significant hereditary angioedema or common variable immune deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Simon Williamson Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>205-870-8803</phone>
    </contact>
    <investigator>
      <last_name>William E Kirby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus- Chandler</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-775-1115</phone>
    </contact>
    <investigator>
      <last_name>Randall J Severance</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research - Glendale</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neil P Sheth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>949-753-1663</phone>
    </contact>
    <investigator>
      <last_name>Elly R Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>951-374-1190</phone>
    </contact>
    <investigator>
      <last_name>Sarah Lavery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>858-278-3674</phone>
    </contact>
    <investigator>
      <last_name>Purvi Mehra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>904-730-0101</phone>
    </contact>
    <investigator>
      <last_name>Carolyn M Tran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark E. Kutner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>352-629-5800</phone>
    </contact>
    <investigator>
      <last_name>David Oliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Judith L White</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>727-544-6367</phone>
    </contact>
    <investigator>
      <last_name>Linda T Murray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>954-260-3999</phone>
    </contact>
    <investigator>
      <last_name>Martin Hale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3522610901</phone>
    </contact>
    <investigator>
      <last_name>Jewel Johnny White</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-494-2227</phone>
    </contact>
    <investigator>
      <last_name>Joseph Newberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-503-1500</phone>
    </contact>
    <investigator>
      <last_name>THOMAS SCHNITZER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>785-354-9591</phone>
    </contact>
    <investigator>
      <last_name>Michael Cox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael J McCartney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corp</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>781-588-5430</phone>
    </contact>
    <investigator>
      <last_name>Egilius Spierings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc.</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>989-895-9100</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Potts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research, LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>636-387-5100</phone>
    </contact>
    <investigator>
      <last_name>Timothy R Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>402-205-7998</phone>
    </contact>
    <investigator>
      <last_name>Jennifer S Kay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>336-574-8020</phone>
    </contact>
    <investigator>
      <last_name>Alexander V. Murray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Nugent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research Inc</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>216-682-0320</phone>
    </contact>
    <investigator>
      <last_name>Joan Rothenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>614-501-6164</phone>
    </contact>
    <investigator>
      <last_name>Samir Arora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>814-693-0300</phone>
    </contact>
    <investigator>
      <last_name>Alan J. Kivitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLC</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert M Griffin Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc.</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>843-856-3784</phone>
    </contact>
    <investigator>
      <last_name>Cynthia B Strout</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>423-990-2478</phone>
    </contact>
    <investigator>
      <last_name>Andrew Brockmyre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>972-241-1221</phone>
    </contact>
    <investigator>
      <last_name>Michelle Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>210-614-7483</phone>
    </contact>
    <investigator>
      <last_name>William P. Jennings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>425-251-1720</phone>
    </contact>
    <investigator>
      <last_name>Leslie Klaff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>7872494763</phone>
    </contact>
    <investigator>
      <last_name>Carlos A Pantojas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/6VXLrQld1Oc5hSVgHZh3OP?conditionId=1lnMwVowG26rZ5LbFd9MZI</url>
    <description>Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants with Osteoarthritis</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

